

False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study

NCT06550986

Status	RECRUITING
Phase	Not Applicable
Sponsor	Shape Memory Medical, Inc.
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (3)

- e18years of age.
- A candidate for false lumen (FL) embolization with a type B dissection, and no prior primary entry tear/TL treatment, OR
- A candidate for FL embolization with a type B or type A dissection, in whom the primary entry tear/TL was treated in a previous procedure, and is now presenting with a FL requiring treatment.

Exclusion (24)

- An inability to provide informed consent.
 - Enrolled in another clinical study other than a registry.
 - Hyperacute or acute aortic dissection (<15 days from symptom onset).
 - Untreated or uncovered primary entry/reentry tear proximal to left subclavian artery (before FL treatment with the investigational product).
 - Vascular disease, aortic rupture, and/or anatomy and/or dissection membrane condition that precludes the safe access and positioning of an introducer sheath and delivery (and expansion) of the investigational product into the FL.
- ... and 19 more (see full listing online)

Locations (2 total)

Auckland City Hospital, Auckland, New Zealand
Waikato Hospital, Hamilton, New Zealand